<DOC>
	<DOCNO>NCT00002185</DOCNO>
	<brief_summary>To determine effect Viracept combination modify antiretroviral therapy outcome cutaneous mucosal Kaposi 's Sarcoma ( KS ) .</brief_summary>
	<brief_title>A Pilot , Open-Label , Phase II , Randomized Study Determine Effects Viracept Outcome Cutaneous Mucosal KS AIDS Patients With CD4 &lt; = 500 Cells/mm3</brief_title>
	<detailed_description>This open-label , randomize , pilot , Phase II study safety efficacy Viracept combination modify antiretroviral therapy treatment patient cutaneous mucosal KS . Patients randomized modify ( add switch initiate ) current antiretroviral therapy add Viracept remain current background antiretroviral therapy 2 month period . Initially 20 patient randomize 2:1 ratio ( i.e. , 14 Viracept , 6 control ) 2 month period . Response therapy evaluate end 2 month control phase . At point , patient initially assign control arm continue open label Viracept additional 10 month period .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIVpositivity . Diagnosed KS proven biopsy . NOTE : Patients must opt immediate topical , systemic radiation treatment . At least 4 cutaneous lesion treat within previous 4 week . Life expectancy &gt; 6 month . Signed , inform consent parent legal guardian patient &lt; 18 year age . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Neoplastic disease ( exclude KS ) require systemic cytotoxic radiation therapy therapy within 1 month baseline completely recover effect therapy . Unstable severe intercurrent medical condition , include limited , significant symptomatic visceral KS . Clinically significant malabsorption syndrome . Renal insufficiency . Patients follow prior condition exclude : Significant Fever ( &gt; 101 degree F ( 38 degree C ) &gt; = 7 day ) and/or diarrhea ( &gt; 6 loose stools/day &gt; = 7 day ) within one month baseline . 1 . Immediate topical systemic treatment KS lesion . Use Retinoid class drug , either topically systemically , betacarotene compound Vitamin A dos 15,000 IU ( 5,000 mcg ) per day concurrently . Immediate radiation treatment . 1 . Treatment KS lesion intralesional chemotherapy within 4 week entry . History &gt; 2 week prior therapy Indinavir Ritonavir . Use Retinoid class drug , either topically systemically , betacarotene compound Vitamin A dos 15,000 IU ( 5,000 mcg ) per day within 4 week entry . Treatment KS lesion radiation within 4 week entry . Active substance abuser ; urine drug test may perform drug abuse suspect .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Skin Neoplasms</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Mucous Membrane</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>